MCDERMOTT, D. F., J. L. LEE, G. A. BJARNASON, J. M. G. LARKIN, R. A. GAFANOV, M. D. KOCHENDERFER, N. V. JENSEN, F. DONSKOV, J. MALIK, Alexandr POPRACH, S. S. TYKODI, T. ALONSO-GORDOA, D. C. CHO, P. F. GEERTSEN, M. A. C. DURAN, C. DISIMONE, R. K. SILVERMAN, R. F. PERINI, C. SCHLOSS a M. B. ATKINS. Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. Journal of clinical oncology. 2318 MILL ROAD, STE 800, ALEXANDRIA, VA: AMER SOC CLINICAL ONCOLOGY, roč. 39, č. 9, s. 1020-1030. ISSN 0732-183X. doi:10.1200/JCO.20.02363. 2021.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
Autoři MCDERMOTT, D. F. (garant), J. L. LEE, G. A. BJARNASON, J. M. G. LARKIN, R. A. GAFANOV, M. D. KOCHENDERFER, N. V. JENSEN, F. DONSKOV, J. MALIK, Alexandr POPRACH (203 Česká republika, domácí), S. S. TYKODI, T. ALONSO-GORDOA, D. C. CHO, P. F. GEERTSEN, M. A. C. DURAN, C. DISIMONE, R. K. SILVERMAN, R. F. PERINI, C. SCHLOSS a M. B. ATKINS.
Vydání Journal of clinical oncology, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA, AMER SOC CLINICAL ONCOLOGY, 2021, 0732-183X.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 50.717
Kód RIV RIV/00216224:14110/21:00124210
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1200/JCO.20.02363
UT WoS 000655499200009
Klíčová slova anglicky Advanced Clear Cell Renal Cell Carcinoma; Pembrolizumab Monotherapy; First-Line Therapy
Štítky 14110811, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 17. 2. 2022 08:27.
Anotace
PURPOSE Pembrolizumab, a programmed death 1 inhibitor, demonstrated promising single-agent activity in untreated patients with various cancer types. The phase II KEYNOTE-427 study evaluated efficacy and safety of single-agent pembrolizumab in treatment-naive patients with advanced clear cell renal cell carcinoma (ccRCC; cohort A) and advanced non-ccRCC (cohort B). Results of cohort A are reported. METHODS In this open-label, single-arm phase II study, patients with advanced ccRCC received pembrolizumab 200 mg every 3 weeks for <= 24 months. The primary end point was objective response rate by RECIST, version 1.1. RESULTS In the total population (N = 110), median time from enrollment to data cutoff was 35.9 (range, 29.5-40.3) months. Objective response rate was 36.4% with four (3.6%) complete responses and 36 (32.7%) partial responses; disease control rate was 58.2% (95% CI, 48.4 to 67.5). Most patients (68.2%) had a decrease in target lesions, including 30.9% with a reduction >= 60%. Median duration of response was 18.9 (range, 2.3-37.6+) months; 64.1% of responders had a response >= 12 months (Kaplan-Meier). Median progression-free survival was 7.1 months (95% CI, 5.6 to 11.0). Median overall survival was not reached; 12-month and 24-month overall survival rates were 88.2% and 70.8%, respectively. Durable responses were observed across all International Metastatic RCC Database Consortium categories. Grade 3-5 treatment-related adverse events were reported in 30.0% of patients, of which colitis and diarrhea were most frequent. CONCLUSION Single-agent pembrolizumab showed promising antitumor activity as a first-line treatment in patients with advanced ccRCC, with durable responses across International Metastatic RCC Database Consortium categories. Safety and tolerability profile of pembrolizumab monotherapy was comparable to what has been previously described in other tumor types.
VytisknoutZobrazeno: 29. 3. 2024 13:21